Fredun Pharmaceuticals Limited has announced the opening of a new manufacturing facility in Palghar, Maharashtra, representing a significant milestone in the company's expansion strategy. The facility marks the addition of the company's fifth manufacturing unit and demonstrates its commitment to strengthening its manufacturing footprint across the healthcare industry.

Facility Specifications and Timeline

The new manufacturing facility spans 40,000 sq. ft. and is expected to become operational by October 2026. This expansion represents a strategic move to enhance the company's production capabilities and meet growing domestic and international demand across its diversified product portfolio.

Strategic Manufacturing Expansion

The facility will support key product categories including veterinary products, supportive nutraceuticals, and pharmaceutical formulations. The company has outlined several expected operational benefits from this expansion, including enhanced efficiency, improved production scalability, and the ability to meet growing market demand.

Additionally, Fredun Pharmaceuticals has planned a 50,000 sq. ft. expansion to be undertaken under strategic growth initiatives, further demonstrating its commitment to scaling operations. The integration with existing facilities is expected to strengthen the company's presence across pharmaceutical and nutraceutical sectors.

Management Commentary

Commenting on the development, Mr. Fredun Medhora, Managing Director, stated: "As our business continues to expand, we are gradually strengthening our manufacturing footprint to stay aligned with our requirements. With opportunities opening up across our key segments, our focus remains on building a stronger and more scalable foundation."

Company Profile and Financial Performance

Fredun Pharmaceuticals Limited operates as a healthcare and pharmaceuticals company offering a diverse range of products. The company's portfolio includes antihypertensives, antidiabetic medications, antiretroviral drugs (ARVs), and narcotics. It is also engaged in manufacturing dietary and herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products.

The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America. With such a diverse product range, the company positions itself as a holistic healthcare provider.

The opening of the fifth manufacturing facility aligns with the company's objective to maintain high standards of quality, compliance, and innovation while strengthening its position as a leading manufacturing partner in the healthcare industry.

Fredun Pharmaceuticals Limited has filed a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the allotment of 40,000 equity shares to its promoter group upon warrant conversion. The regulatory filing, submitted on April 13, 2026, provides detailed shareholding changes resulting from the warrant conversion completed on April 09, 2026.

SEBI SAST Disclosure Details

The disclosure filed with BSE Limited reveals comprehensive shareholding patterns of the promoter group before and after the warrant conversion. Company Secretary and Compliance Officer Vaishnavi Sahu submitted the mandatory filing, which shows the promoter group's total holding and voting rights.

Warrant Conversion Transaction

The allotment involved conversion of warrants into 40,000 equity shares by Mrs. Daulat Nariman Medhora, a promoter and Whole Time Director. The conversion was executed at ₹1,250 per share, with a face value of ₹10 each and premium of ₹1,240 per share.

Share Capital Changes

The warrant conversion resulted in changes to the company's share capital structure. The paid-up capital increased from ₹5,47,26,900 to ₹5,51,26,900, while the diluted share capital stands at ₹5,91,76,220 after considering outstanding convertible securities.

Regulatory Compliance Framework

The disclosure was filed in accordance with SEBI (SAST) Regulations, 2011, which mandate reporting of substantial acquisitions and changes in shareholding patterns. The promoter group's acquisition through warrant conversion required disclosure as it involved changes in voting rights and shareholding percentages. The filing includes detailed calculations based on total share capital and diluted share capital, ensuring transparency in ownership structure changes.

The company maintains its listing on BSE Limited and continues to comply with all applicable disclosure requirements under SEBI regulations. The warrant conversion represents the completion of a preferential issue process that began with shareholder approvals in October 2025.